Meta-analysis shows no significant associations for children, adolescents, or adults, for female patients, or for those with preexisting CVD
FRIDAY, Dec. 2, 2022 (HealthDay News) — There seems to be no statistically significant association between attention-deficit/hyperactivity disorder (ADHD) medications and cardiovascular disease (CVD) risk, according to a systematic review and meta-analysis published online Nov. 23 in JAMA Network Open.
Le Zhang, M.P.H., from the Karolinska Institutet in Stockholm, and colleagues reviewed observational studies examining the association between ADHD medications and risk for CVD. Data were included from 19 studies with 3,931,532 children, adolescents, and adults; 14 of these studies were cohort studies and were included in the meta-analysis.
The researchers found that the pooled adjusted relative risk (RR) did not indicate a statistically significant association between ADHD medication use and any CVD among children and adolescents, young or middle-aged adults, or older adults (RRs [95 percent confidence intervals (CIs)], 1.18 [0.91 to 1.53], 1.04 [0.43 to 2.48], and 1.59 [0.62 to 4.05], respectively). No significant associations were observed for stimulants or nonstimulants (RRs [95 percent CIs], 1.24 [0.84 to 1.83] and 1.22 [0.25 to 5.97], respectively). No statistically significant association was found for cardiac arrest or arrhythmias (RR, 1.60; 95 percent CI, 0.94 to 2.72), cerebrovascular diseases (RR, 0.91; 95 percent CI, 0.72 to 1.15), or myocardial infarction (RR, 1.06; 95 percent CI, 0.68 to 1.65). In female patients and those with preexisting CVD, no associations were observed (RRs [95 percent CIs], 1.88 [0.43 to 8.24] and 1.31 [0.80 to 2.16], respectively).
“Health care professionals must exercise caution and not slavishly adhere to consensus guidelines or follow conclusions from meta-analyses when treating individual patients,” writes the author of an accompanying editorial. “Every treatment decision is a balance of potential harm and potential benefit, and that balance is different for every individual patient.”
Two authors disclosed financial ties to the pharmaceutical industry.
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
